Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.53 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.53 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.53 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787971 | 0.90 | KMT2A (0.49) | SMN1; SMN2ALDH1A1KMT2AHPGDMAPT | |
| SCHEMBL1657680 | 0.86 | TAAR1 (0.50) | SMN1; SMN2KMT2AHPGDMEN1HDAC3 | |
| SCHEMBL1658883 | 0.86 | KMT2A (0.54) | ALDH1A1KMT2AHPGDMEN1RXFP1 | |
| SCHEMBL1786050 | 0.86 | HDAC3 (0.58) | KMT2AHPGDMEN1HDAC3HDAC1 | |
| SCHEMBL23417641 | 0.83 | SMN1; SMN2 (0.84) | SMN1; SMN2ALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL1658857 | 0.80 | EPHX2 (0.54) | SMN1; SMN2ALDH1A1KMT2AMAPTHDAC3 | |
| SCHEMBL2059289 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL1658948 | 0.79 | PLAAT3 (0.49) | SMN1; SMN2ALDH1A1KMT2AHPGDPLAAT3 | |
| SCHEMBL1659441 | 0.79 | HPGD (0.59) | HPGDTAAR1 | |
| SCHEMBL1658955 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMEN1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262508-B1 | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | BIOELECTRON TECH CORP (US) | 2018-10-03 | — | — | EP | claimed |
| EP-2262508-B1 | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | BIOELECTRON TECH CORP (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9090576-B2 | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140329860-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8716527-B2 | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110124679-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | PTC THERAPEUTICS, INC. | 2011-05-26 | — | — | US | disclosed |
| EP-2262508-A2 | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | Edison Pharmaceuticals, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009111576-A2 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124679-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | NQO1, TXNRD2, MT-ND2 | SMN1; SMN2 302/4885ALDH1A1 413/4885KMT2A 2889/4885 |
| US-20140329860-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | NQO1, TXNRD2, MT-ND2 | SMN1; SMN2 302/4885ALDH1A1 413/4885KMT2A 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.